Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms
VR

VRTX

Market Closed

Vertex Pharmaceuticals Incorporated

NASDAQHealthcareBiotechnology
US
6.40K employees
CEO: Reshma Kewalramani
Founded: 1991
$496.07
+$0.00(+NaN%)
Market Cap
125.91B
Beta
0.29
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Vertex trades 9.2% above its high-confidence fair value of $438.27, signaling potential overvaluation. Financial health is strong across liquidity, profitability, and leverage, but Monte Carlo analysis shows high volatility with a downside risk of 70.6%. The wide valuation range and pronounced volatility imply elevated investment risk despite solid fundamentals.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore VRTX

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

VRTX in the Healthcare

Large Cap
Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →